Claims for Patent: 10,383,875

Summary for Patent: 10,383,875

Title:	Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
Abstract:	The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.
Inventor(s):	Buderer; Matthew J. (Oak Harbor, OH), Saadeh; Dennis (San Diego, CA), Boll; Andrew R. (San Diego, CA)
Assignee:	HARROW IP, LLC (San Diego, CA)
Application Number:	15/620,430
Patent Claims:	1. A method for treating a fibrotic disease in a subject in need thereof, comprising locally administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical formulation, the formulation comprising: (a) a quantity of a compound of formula I: ##STR00008## or a pharmaceutically acceptable salt thereof, wherein each of R.sup.1 , R.sup.2 and R.sup.3 is independently selected from the group consisting of H, a C.sub.1-C.sub.6 alkyl, a C.sub.2-C.sub.6 alkenyl, a C.sub.2-C.sub.6 alkynyl, a cycloalkyl, a heterocyclyl, an aryl, and heteroaryl, each of which is optionally substituted; and (b) a quantity of a polysaccharide selected from the group consisting of hyaluronic acid, heparin, heparan, chondroitin, dermatan, keratin, and pharmaceutically acceptable water-soluble salts thereof. 2. The method of claim 1, wherein each of R.sup.1, R.sup.2 and R.sup.3 is independently selected from the group consisting of H and an optionally substituted C.sub.1-C.sub.6 alkyl. 3. The method of claim 1, wherein the compound of formula I is selected from the group consisting of pentoxifylline, caffeine, aminophylline, enprofylline, isbufylline, theophylline, theobromine, and 3-isobutyl-1-methylxanthine. 4. The method of claim 1, wherein the fibrotic disease is Peyronie's disease. 5. The method of claim 1, wherein administration of the formulation leads to improvement of erectile dysfunction. 6. The method of claim 1, wherein the pharmaceutical formulation has a pH of between 5.5 and 6. 7. The method of claim 1, wherein the therapeutically effective amount is between 4 mg and 20 mg. 8. The method of claim 1, wherein the pharmaceutical formulation is administered locally to the penis of the subject. 9. The method of claim 8, wherein the pharmaceutical formulation is administered by intracavernosal injection. 10. The method of claim 1, wherein the pharmaceutical formulation further comprises a second active agent selected from the group consisting of alprostadil, papaverine, and phentolamine. 11. The method of claim 1, wherein the pharmaceutical formulation further comprises a collagenase. 12. A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula I: ##STR00009## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof; a quantity of a polysaccharide selected from the group consisting of hyaluronic acid, heparin, heparan, chondroitin, dermatan, keratin, and pharmaceutically acceptable water-soluble salts thereof; and a pharmaceutically acceptable excipient or carrier suitable for local administration, wherein each of R.sup.1, R.sup.2 and R.sup.3 is independently selected from the group consisting of H, a C.sub.1-C.sub.6 alkyl, a C.sub.2-C.sub.6 alkenyl, a C.sub.2-C.sub.6 alkynyl, a cycloalkyl, a heterocyclyl, an aryl, and heteroaryl, each of which is optionally substituted. 13. The formulation of claim 12, wherein each of R.sup.1, R.sup.2 and R.sup.3 is independently selected from the group consisting of H a C.sub.1-C.sub.6 alkyl, and a substituted C.sub.1-C.sub.6 alkyl. 14. The formulation of claim 12 wherein the compound of formula I is selected from the group consisting pentoxifylline, caffeine, aminophylline, enprofylline, isbufylline, theophylline, theobromine, and 3-isobutyl-1-methylxanthine. 15. The formulation of claim 12, having a pH of between 5.5 and 6. 16. The formulation of claim 12, wherein the therapeutically effective amount is between 4 mg and 20 mg. 17. The formulation of claim 12, further comprising a sterile liquid composition and wherein the excipient or carrier is suitable for intracavernosal injection. 18. The pharmaceutical formulation of claim 12, further comprising an additional active agent selected from the group consisting of alprostadil, papaverine, and phentolamine. 19. The pharmaceutical formulation of claim 12, further comprising a collagenase. 20. The pharmaceutical formulation of claim 12, further comprising an active agent selected from the group consisting of at least one anesthetic, at least one anti-bacterial agent, at least one antiviral medicament, at least one antifungal medicament and combinations thereof. 21. The pharmaceutical formulation of claim 20, wherein the anesthetic is selected from the group consisting of lidocaine, tetracaine, proparacaine, procaine, dyclonine and combinations thereof. 22. The formulation of claim 12, wherein the formulation is ensconced within essentially spherical particles fabricated of a water soluble biodegradable polymer selected from the group consisting of poly(lactic acid-co-glycolic acid), poly(lactic acid), poly(glycolic acid), poly(caprolactone), and poly(hydroxybutyrate). 23. A pharmaceutical composition comprising essentially spherical particles incorporating a therapeutically effective amount of a compound of formula I: ##STR00010## or a pharmaceutically acceptable salt, ester, amide or prodrug thereof and a pharmaceutically acceptable excipient or carrier suitable for local administration, wherein each of R.sup.1 , R.sup.2 and R.sup.3 is independently selected from the group consisting of H, a C.sub.1-C.sub.6 alkyl, a C.sub.2-C.sub.6 alkenyl, a C.sub.2-C.sub.6 alkynyl, a cycloalkyl, a heterocyclyl, an aryl, and heteroaryl, each of which is optionally substituted, wherein the particles are fabricated of a water soluble biodegradable polymer selected from the group consisting of poly(lactic acid-co-glycolic acid), poly(lactic acid), poly(glycolic acid), poly(caprolactone), and poly(hydroxybutyrate).

Details for Patent 10,383,875

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	June 04, 1965		2037-06-12